July 19, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3
Trial ofIV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS)TOKYO, Japan, July 19, 2016 -- SymBio Pharmaceuticals Limited (Headquarters:Tokyo, “SymBio”) announced today that the first patient has been enrolled in Japan for
the global randomized Phase 3 trial of the novel, RAS pathway targeted anti-cancer
drug IV rigosertib in relapsed/refractory patients with higher-risk myelodysplastic
syndromes (MDS) after failure of hypomethylating agent therapy.
SymBio is participating in the global randomized Phase 3 trial for IV rigosertib (“04-30”
or “INSPIRE” trial) conducted by SymBio’s U.S. partner, Onconova Therapeutics, Inc.
(Headquarters: Newtown, PA).

SymBio completed a Phase 1 clinical trial of IV

rigosertib in Japan in October, 2015.

Patients are currently being enrolled in theINSPIRE trial at more than 90 sites in the U.S., Europe and Japan.
The INSPIRE trial is designed to enroll 225 patients, including more than 20 patients
expected to be enrolled in Japan, corresponding to approximately 10% of the total.
Following completion of the INSPIRE trail, SymBio is planning to submit new drug
applications in Japan concurrently with submission in the U.S.
SymBio obtained the licensing rights for rigosertib in July, 2011 and retains thedevelopment rights for Japan and Korea.
This event will not impact the Company’s current financial forecast.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About Myelodysplastic Syndromes (MDS)MDS patients often require frequent blood transfusions due to the development ofsevere anemia (decrease in the number of red blood cells), with a high rate ofprogression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS
patients in Japan alone, with the number of cases expected to increase as thepopulation ages. MDS and AML are widely recognized as two blood disorders that aredifficult to manage given the limited therapeutic options available for patients,
particularly for patients who have a drug-resistant form of the disease. A high unmet
medical need clearly exists for the establishment of new effective therapies to treat both
lower-risk MDS and higher-risk MDS.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on
discovering and developing novel products to treat cancer. Onconova's clinical andpre-clinical stage drug development candidates are derived from its extensive chemical
library and are designed to work against specific cellular pathways that are importantin cancer cells, while causing minimal damage to normal cells. In addition to rigosertib,
Onconova's most advanced drug candidate under development, two other drugcandidates are in clinical trials and several other compounds in the pre-clinical stage ofdevelopment. For more information, please visit http://www.onconova.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida
who previously served concurrently as Corporate VP of Amgen Inc. and founding
President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned
subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park,California, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as
it aspires to be a leading global specialty biopharmaceutical company dedicated toaddressing underserved medical needs with main therapeutic focus in oncology,
hematology and pain management.